Nippon Kayaku

4272 · TSE · Japan

Public Market Listing

4272TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Nippon Kayaku are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
ROS1Small molecule
Non-Small Cell Lung Cancer
ROS1-Positive Non-Small Cell Lung Cancer
Darinaparsin(Darvias)No recent activity
Phase 2
apoptosis via reactive oxygen species (ROS) generation and mitochondrial disruptionSmall molecule
Non-Hodgkin Lymphoma
Peripheral T-Cell Lymphoma

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
January 2029 (1)
TaletrectinibPhase 3Non Small Cell Lung Cancer
Est. primary completion 2029-01 · NCT06564324 · CT.gov ↗
What to watch
2030 (1)
August 2030 (1)
TaletrectinibPhase 3Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2030-08-30 · NCT07154706 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

4 January 2027FDA action dateTaletrectinibFDA target action date for IBTROZI sNDA
US, FDA · Source ↗

Recent

16 September 2026ApprovalTaletrectinibFDA approves IBTROZI supplemental application with updated duration of response
US, FDA · Nuvation Bio Inc. · Source ↗
29 June 2026Filing acceptedTaletrectinibUK MHRA validates taletrectinib MAA
UK, MHRA · Source ↗
June 2026Filing acceptedTaletrectinibMHRA validates taletrectinib marketing authorisation application
UK, MHRA · Nuvation Bio Inc. and Eisai · Source ↗
6 May 2026Filing acceptedTaletrectinibFDA accepts sNDA for IBTROZI with updated duration of response data
US, FDA · Source ↗
March 2026Filing acceptedTaletrectinibEMA validates taletrectinib marketing authorisation application
EU, EMA · Nuvation Bio Inc. and Eisai · Source ↗

Financial reports

No financial reports recorded.